Fresenius Kabi has acquired from Becton, Dickinson and Company (BD) the BD Rx business, which includes a pharmaceutical manufacturing plant in Wilson, North Carolina, and the BD line of seven drugs in ready-to-administer prefilled glass syringes. Fresenius Kabi and BD have also signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous (IV) solutions.

The North Carolina plant, which employs about 100 people, features advanced pharmaceutical manufacturing and packaging technologies, and was approved by the US Food and Drug Administration in 2012. It currently produces seven drugs in ready-to-administer prefilled syringes and has capacity for future growth. Fresenius Kabi expects to invest in the facility over time, making it its global center of excellence for prefilled syringe production. The two companies will work together to assure a smooth transition for employees and customers.

Source: Fresenius Kabi